Items where authors include "Wardley, A."

Article

Coakley, M. orcid.org/0000-0003-2658-7789, Villacampa, G. orcid.org/0000-0003-4868-6585, Sritharan, P. orcid.org/0009-0004-9733-3596 et al. (21 more authors) (2024) Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer. Clinical Cancer Research, 30 (4). pp. 895-903. ISSN 1078-0432

Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 24 (12). pp. 1359-1374. ISSN 1470-2045

Coombes, R.C., Tovey, H., Kilburn, L. et al. (230 more authors) (2021) Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer. JAMA Oncology, 7 (9). p. 1291. ISSN 2374-2437

Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045